Matchpoint Therapeutics Appoints John O’Malley as Chief Medical Officer

WATERTOWN, Mass., Oct. 14, 2026 /CourierPR/ -- Matchpoint Therapeutics, a biotechnology company based in Watertown, Massachusetts, has expanded its leadership team with the appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer. This move comes on the heels of the company’s recent $150 million Series B financing, aimed at advancing its pipeline of first-in-class oral small molecules into clinical development for autoimmune and inflammatory diseases.

O’Malley brings extensive experience in immunology clinical development, having previously held leadership roles at CRISPR Therapeutics and Sanofi. At CRISPR Therapeutics, he served as Vice President and Head of Translational Medicine, where he led a cross-functional team responsible for the advancement of a clinical-stage allogeneic CAR T-cell therapy. His experience also includes managing the company’s clinical translation efforts. Prior to CRISPR Therapeutics, O’Malley gained valuable experience advancing immunology medicines at Sanofi. As Global Clinical Leader for amlitelimab, he led clinical development across all indications, overseeing a broad portfolio of mid- and late-stage trials. His previous roles also include a key role in expanding Dupixent® into pediatric atopic dermatitis and prurigo nodularis, where he served as a Senior Clinical Director.

O’Malley’s academic background includes a postdoctoral fellowship in dermatology at Harvard Medical School and a position as Chief Dermatology Resident at New York-Presbyterian Hospital / Columbia University Irving Medical Center. He earned his M.D. and Ph.D. in Microbiology and Immunology from Indiana University and his B.S., summa cum laude, from the University of Notre Dame.

Andre Turenne, Chief Executive Officer of Matchpoint Therapeutics, expressed enthusiasm about O’Malley’s appointment.

Matchpoint Therapeutics is a privately held biotechnology company pioneering the discovery of precision covalent medicines. The company’s discovery engine integrates deep expertise across chemical biology, covalent chemistry, structure-based drug design, and computational sciences. The company’s focused deployment of its platform has produced a pipeline of first-in-class programs and a discovery collaboration with Novartis.